Are you working on an antibody test for COVID-19?
Products are for professional/laboratory use only. Improve your blocking agent, antibody specificity, enzyme activity with a BSA alternative: 5D Protein Stabilizer
25May
News
14May
New Antibodies Available From Cell Marque
The below antibodies are now available from Cell Marque:
20Mar
Cell Marque SDHB antibody for GIST now available
Cell Marque™ Tissue Diagnostics SDHB (EP288) is now available. Succinate dehydrogenase B (SDHB) is a useful antibody for subtyping Gastrointestinal stromal tumours (GIST).
31Jan
HSV II Now Available from Cell Marque
Herpes Simplex Virus II Rabbit Polyclonal Antibody
Herpes simplex virus is quite ubiquitous and is quite variable in its presentation in human disease.
14Dec
Tips on Flow Cytometry Controls
Controls are vital in any experiment to reliably distinguish your results from background variation and non-specific effects. Here we will discuss some essential controls for flow cytometry you must consider to ensure publication quality flow cytometry data.
18May
Novel Dermatopathology Markers
We are pleased to highlight the Novel Dermatopathology Markers available from Cell Marque.
04Feb
Spotlight on NKX3.1
NKX3.1 is a prostate-specific homeobox gene protein whose expression is predominantly localized to prostate epithelium. It acts as a transcription factor involved in prostate development. Anti-NKX3.1 labels prostate epithelium, both malignant and benign, with a nuclear visualization. Studies have shown that NKX3.1 immunostaining compares favorably to PSA immunostaining in sensitivity of metastatic prostate adenocarcinoma.1 NKX3.1 is recommended to be included in a diagnostic panel with PSA, PSAP, cytokeratin 34betaE12, and GATA3.2
21Jan
Novel Nuclear Transcription Factors for Prostate:
Over 220,000 men are diagnosed in the United States each year with prostate cancer, and over 27,000 deaths occur annually as a result.1 Early detection and definitive diagnosis is important! Scientific advancements in cancer detection have developed rapidly to keep up with the prevalence of this disease. Recent detection advancements include the development of antibodies NKX3.1 and ERG. These transcription factors aid in the immunohistochemical diagnosis of prostate cancer.
14Jan
